Quick Answer
AYTU BIOPHARMA, INC reported Revenue From Contract With Customer Excluding Assessed Tax of $66.38 million for the year ending 2025.
- AYTU BIOPHARMA, INC showed an increase of +1.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from AYTU BIOPHARMA, INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), AYTU BIOPHARMA, INC's Revenue From Contract With Customer Excluding Assessed Tax has grown by 140.2%.
- Historical annual values: Fiscal year 2025: $66.38 million | Fiscal year 2024: $65.18 million | Fiscal year 2023: $107.40 million | Fiscal year 2022: $96.67 million | Fiscal year 2021: $65.63 million | Fiscal year 2020: $27.63 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: